Therapeutic potential of mesenchymal stem cells for diabetes

    1. Peter Hornsby2
    1. 1Department of Pediatrics, University of Texas Health Science Center-San Antonio, San Antonio, Texas, USA
    2. 2Department of Physiology, Texas Research Park Campus, Barshop Institute for Longevity and Aging Studies, San Antonio, Texas, USA
    1. Correspondence should be addressed to A Moreira; Email: moreiraa{at}


    Mesenchymal stem cells (MSCs) are self-renewing multipotent cells that have the capacity to secrete multiple biologic factors that can restore and repair injured tissues. Preclinical and clinical evidence have substantiated the therapeutic benefit of MSCs in various medical conditions. Currently, MSCs are the most commonly used cell-based therapy in clinical trials because of their regenerative effects, ease of isolation and low immunogenicity. Experimental and clinical studies have provided promising results using MSCs to treat diabetes. This review will summarize the role of MSCs on tissue repair, provide emerging strategies to improve MSC function and describe how these processes translate to clinical treatments for diabetes.

    • Received 18 July 2017
    • Accepted 24 July 2017
    • Made available online as an Accepted Preprint 24 July 2017
    | Table of Contents